New collaboration aims to bring population-scale whole-genome sequencing into everyday healthcare, enabling earlier risk detection and data-driven preventionSAN DIEGO, March 16, 2026 /PRNewswire/ -- Illumina, Inc.

<p xmlns="http://www.w3.org/1999/xhtml" class="prntac"><i xmlns="http://www.w3.org/1999/xhtml">New collaboration aims to bring population-scale whole-genome sequencing into everyday healthcare, enabling earlier risk detection and data-driven prevention</i></p><p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">SAN DIEGO</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">March 16, 2026</span> /PRNewswire/ -- Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/ILMN">ILMN</a>) today announced a strategic collaboration with Veritas Genetics Powered By Fuze Health to form a consortium that aims to bring preventive genomics into everyday healthcare through health insurance plans in the United States and under other global markets, setting a new standard for proactive health management. By combining clinical-grade sequencing, advanced informatics, and member-ready reporting, the collaboration supports an integrated data ecosystem to advance research, drug discovery, and clinical trial optimization.</p>
<p xmlns="http://www.w3.org/1999/xhtml">Built around a shared vision for data-driven precision medicine, the collaboration aims to integrate whole-genome sequencing into proactive healthcare. It will empower individuals to proactively leverage whole-genome data to support earlier identification of disease risk, more personalized prevention strategies, and improved long-term health outcomes.</p><p xmlns="http://www.w3.org/1999/xhtml">&#34;Genomics is increasingly moving upstream in healthcare, from diagnosing disease to helping prevent it,&#34; said Rami Mehio, general manager, BioInsight at Illumina. &#34;By combining Illumina&#39;s sequencing and informatics backbone with Veritas&#39; patient-ready reporting, this collaboration represents an important step forward in making preventive genomics actionable, accessible, and integrated into everyday healthcare.&#34;</p><p xmlns="http://www.w3.org/1999/xhtml">&#34;The myGenome whole-genome sequencing comprehensive genetic risk service has been developed to integrate into a health insurer&#39;s environment and enable members to benefit from preventive genomics at a personalized level,&#34; said Javier de Echevarría, CEO, Veritas Genetics and Chief Genomics Officer, Fuze Health.</p><p xmlns="http://www.w3.org/1999/xhtml">The consortium is designed to provide:</p><ul xmlns="http://www.w3.org/1999/xhtml" type="disc"><li xmlns="http://www.w3.org/1999/xhtml">An opt-in preventive genomics program that delivers actionable genomic insights and connects those insights to appropriate interventions.</li><li xmlns="http://www.w3.org/1999/xhtml">Integrated care pathways for actionable findings, including confirmatory testing, specialist referral where appropriate, guideline-aligned screening, and prevention programs.</li><li xmlns="http://www.w3.org/1999/xhtml">A streamlined member experience supported by simple sample collection, clear education and consent, results delivery, and access to genetic counseling.</li><li xmlns="http://www.w3.org/1999/xhtml">A consented, integrated clinical-genomics dataset to enable industry partnerships across precision medicine.</li></ul><p xmlns="http://www.w3.org/1999/xhtml">The collaboration is structured around distinct but complementary roles, where Veritas has elected to build and validate workflows based on Illumina sequencing and informatics technologies; including WGS, DRAGEN analysis methods and pipelines, and AI enabled insights. Veritas will provide the experience layer, including interpretation capabilities with myGenome reporting, clinical interpretation, and access to genetic counseling services. The collaboration also seeks to create opportunities to leverage the full breadth of Fuze Health capabilities to support bringing genomic insights into care pathways.</p><p xmlns="http://www.w3.org/1999/xhtml">Together, the consortium aims to enable earlier identification of elevated risk across areas such as hereditary cancer, cardiometabolic disease, and medication response, helping shift care from reactive treatment to proactive prevention. This initiative builds on Illumina&#39;s broader strategy to expand the clinical utility of genomics and support scalable, evidence-based adoption across the healthcare ecosystem.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">Use of forward-looking statements</b></p><p xmlns="http://www.w3.org/1999/xhtml">This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) our and our partners&#39; ability to deploy new products, services, and applications, and to expand the markets for genomics-related products and services; and (ii) the challenges associated with multiparty collaborations, including our reliance on the performance of such partners,  together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts&#39; expectations, or to provide interim reports or updates on the progress of the current quarter.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">About Illumina</b> </p><p xmlns="http://www.w3.org/1999/xhtml">Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit <a xmlns="http://www.w3.org/1999/xhtml" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4641435-1&amp;h=3814622648&amp;u=https%3A%2F%2Fwww.illumina.com%2F&amp;a=illumina.com" target="_blank" rel="nofollow">illumina.com</a> and connect with us on <a xmlns="http://www.w3.org/1999/xhtml" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4641435-1&amp;h=3050877918&amp;u=https%3A%2F%2Ftwitter.com%2Fillumina&amp;a=X" target="_blank" rel="nofollow">X</a>, <a xmlns="http://www.w3.org/1999/xhtml" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4641435-1&amp;h=1282341048&amp;u=https%3A%2F%2Fwww.facebook.com%2Filluminainc&amp;a=Facebook" target="_blank" rel="nofollow">Facebook</a>, <a xmlns="http://www.w3.org/1999/xhtml" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4641435-1&amp;h=3267236543&amp;u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fillumina&amp;a=LinkedIn" target="_blank" rel="nofollow">LinkedIn</a>, <a xmlns="http://www.w3.org/1999/xhtml" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4641435-1&amp;h=2728386269&amp;u=https%3A%2F%2Fwww.instagram.com%2Filluminainc&amp;a=Instagram" target="_blank" rel="nofollow">Instagram</a>, <a xmlns="http://www.w3.org/1999/xhtml" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4641435-1&amp;h=3102379406&amp;u=https%3A%2F%2Fwww.tiktok.com%2F%40illuminainc&amp;a=TikTok" target="_blank" rel="nofollow">TikTok</a>, and <a xmlns="http://www.w3.org/1999/xhtml" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4641435-1&amp;h=661781424&amp;u=https%3A%2F%2Fwww.youtube.com%2Fuser%2FIlluminaInc&amp;a=YouTube" target="_blank" rel="nofollow">YouTube</a><u xmlns="http://www.w3.org/1999/xhtml">.</u> </p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">About Veritas Genetics Powered by Fuze Health</b></p><p xmlns="http://www.w3.org/1999/xhtml">Veritas Genetics is a leader in clinical genomics, offering advanced human-genome sequencing and interpretation services to enable accurate diagnosis, personalized prevention, and improved healthcare decision-making. Veritas is part of Fuze Health, a technology-powered home health screening, genomics and pharmacy services provider committed to transforming patient experiences and enabling healthcare partners – including care providers, health plans, employers and life sciences companies – to excel in an outcomes-focused system.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">Contacts</b>  </p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">Investors:</b> <br xmlns="http://www.w3.org/1999/xhtml"></br>Illumina Investor Relations <br xmlns="http://www.w3.org/1999/xhtml"></br>858-291-6421 <br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" href="mailto:IR@illumina.com" target="_blank" rel="nofollow">IR@illumina.com</a> </p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">Media:</b> <br xmlns="http://www.w3.org/1999/xhtml"></br>Christine Douglass <br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" href="mailto:PR@illumina.com" target="_blank" rel="nofollow">PR@illumina.com</a> </p>



<p xmlns="http://www.w3.org/1999/xhtml" id="PURL"><img xmlns="http://www.w3.org/1999/xhtml" title="Cision" width="12" height="12" alt="Cision" src="https://edge.prnewswire.com/c/img/favicon.png?sn=LA10450&amp;sd=2026-03-16"></img> View original content:<a xmlns="http://www.w3.org/1999/xhtml" id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/illumina-advances-preventive-genomics-through-strategic-consortium-with-veritas-genetics-302714332.html" target="_blank">https://www.prnewswire.com/news-releases/illumina-advances-preventive-genomics-through-strategic-consortium-with-veritas-genetics-302714332.html</a></p><p xmlns="http://www.w3.org/1999/xhtml">SOURCE Illumina, Inc.</p>

ILMN

Illumina advances preventive genomics through strategic consortium with Veritas Genetics

Illumina Collaborates with Veritas to Enhance Preventive Genomics Healthcare

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>New collaboration aims to bring population-scale whole-genome sequencing into everyday healthcare, enabling earlier risk detection and data-driven preventionSAN DIEGO, March 16, 2026 /PRNewswire/ -- Illumina, Inc.</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Illumina has announced a strategic collaboration with Veritas Genetics to integrate preventive genomics into everyday healthcare. This partnership aims to utilize whole-genome sequencing for proactive risk identification and personalized prevention, potentially positioning ILMN for expanded market opportunities and revenue growth.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Illumina partners with Veritas Genetics for preventive genomics integration.</li><li>The collaboration aims to enhance proactive healthcare using genomic data.</li><li>Focus on actionable insights for disease risk and prevention strategies.</li><li>Targets hereditary cancer, cardiometabolic disease, and medication response risks.</li><li>Advancement supports scalable adoption in the healthcare ecosystem.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Veritas Genetics (Not Publicly Traded)</strong>: Partner enhancing preventive genomics, leveraging Illumina&#039;s technologies.</li><li><strong>Fuze Health (Not Publicly Traded)</strong>: Supports transforming healthcare with data-driven genomics insights.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This news falls under &#039;Corporate Developments&#039; due to the strategic collaboration aimed at enhancing healthcare solutions. The partnership&#039;s focus on proactive health management underscores the growing importance of genomics in clinical settings.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>The consortium aims to expand Illumina&#039;s market reach in preventive genomics.</li><li>Successful implementation could lead to higher adoption rates of genomic services.</li><li>Potential enhanced partnerships may improve revenue streams across various healthcare sectors.</li><li>Increased focus on proactive health management may boost Illumina&#039;s stock price.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Partnership announced on March 16, 2026.</li><li>Focus on integrating whole-genome sequencing into health insurance models.</li><li>Targeting hereditary disease prevention, cardiometabolic conditions, and medication response.</li><li>Combination of Illumina&#039;s sequencing tech and Veritas&#039; reporting tailored for patients.</li><li>Aims to create an integrated clinical-genomics dataset for research and partnerships.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Consider buying ILMN as this collaboration may drive revenue growth in the near term.</p>
  </section>
</section>


<p xmlns="http://www.w3.org/1999/xhtml" class="prntac"><i xmlns="http://www.w3.org/1999/xhtml">New collaboration aims to bring population-scale whole-genome sequencing into everyday healthcare, enabling earlier risk detection and data-driven prevention</i></p><p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">SAN DIEGO</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">March 16, 2026</span> /PRNewswire/ -- Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/ILMN">ILMN</a>) today announced a strategic collaboration with Veritas Genetics Powered By Fuze Health to form a consortium that aims to bring preventive genomics into everyday healthcare through health insurance plans in the United States and under other global markets, setting a new standard for proactive health management. By combining clinical-grade sequencing, advanced informatics, and member-ready reporting, the collaboration supports an integrated data ecosystem to advance research, drug discovery, and clinical trial optimization.</p>
<p xmlns="http://www.w3.org/1999/xhtml">Built around a shared vision for data-driven precision medicine, the collaboration aims to integrate whole-genome sequencing into proactive healthcare. It will empower individuals to proactively leverage whole-genome data to support earlier identification of disease risk, more personalized prevention strategies, and improved long-term health outcomes.</p><p xmlns="http://www.w3.org/1999/xhtml">&#34;Genomics is increasingly moving upstream in healthcare, from diagnosing disease to helping prevent it,&#34; said Rami Mehio, general manager, BioInsight at Illumina. &#34;By combining Illumina&#39;s sequencing and informatics backbone with Veritas&#39; patient-ready reporting, this collaboration represents an important step forward in making preventive genomics actionable, accessible, and integrated into everyday healthcare.&#34;</p><p xmlns="http://www.w3.org/1999/xhtml">&#34;The myGenome whole-genome sequencing comprehensive genetic risk service has been developed to integrate into a health insurer&#39;s environment and enable members to benefit from preventive genomics at a personalized level,&#34; said Javier de Echevarría, CEO, Veritas Genetics and Chief Genomics Officer, Fuze Health.</p><p xmlns="http://www.w3.org/1999/xhtml">The consortium is designed to provide:</p><ul xmlns="http://www.w3.org/1999/xhtml" type="disc"><li xmlns="http://www.w3.org/1999/xhtml">An opt-in preventive genomics program that delivers actionable genomic insights and connects those insights to appropriate interventions.</li><li xmlns="http://www.w3.org/1999/xhtml">Integrated care pathways for actionable findings, including confirmatory testing, specialist referral where appropriate, guideline-aligned screening, and prevention programs.</li><li xmlns="http://www.w3.org/1999/xhtml">A streamlined member experience supported by simple sample collection, clear education and consent, results delivery, and access to genetic counseling.</li><li xmlns="http://www.w3.org/1999/xhtml">A consented, integrated clinical-genomics dataset to enable industry partnerships across precision medicine.</li></ul><p xmlns="http://www.w3.org/1999/xhtml">The collaboration is structured around distinct but complementary roles, where Veritas has elected to build and validate workflows based on Illumina sequencing and informatics technologies; including WGS, DRAGEN analysis methods and pipelines, and AI enabled insights. Veritas will provide the experience layer, including interpretation capabilities with myGenome reporting, clinical interpretation, and access to genetic counseling services. The collaboration also seeks to create opportunities to leverage the full breadth of Fuze Health capabilities to support bringing genomic insights into care pathways.</p><p xmlns="http://www.w3.org/1999/xhtml">Together, the consortium aims to enable earlier identification of elevated risk across areas such as hereditary cancer, cardiometabolic disease, and medication response, helping shift care from reactive treatment to proactive prevention. This initiative builds on Illumina&#39;s broader strategy to expand the clinical utility of genomics and support scalable, evidence-based adoption across the healthcare ecosystem.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">Use of forward-looking statements</b></p><p xmlns="http://www.w3.org/1999/xhtml">This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) our and our partners&#39; ability to deploy new products, services, and applications, and to expand the markets for genomics-related products and services; and (ii) the challenges associated with multiparty collaborations, including our reliance on the performance of such partners,  together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts&#39; expectations, or to provide interim reports or updates on the progress of the current quarter.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">About Illumina</b> </p><p xmlns="http://www.w3.org/1999/xhtml">Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit <a xmlns="http://www.w3.org/1999/xhtml" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4641435-1&amp;h=3814622648&amp;u=https%3A%2F%2Fwww.illumina.com%2F&amp;a=illumina.com" target="_blank" rel="nofollow">illumina.com</a> and connect with us on <a xmlns="http://www.w3.org/1999/xhtml" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4641435-1&amp;h=3050877918&amp;u=https%3A%2F%2Ftwitter.com%2Fillumina&amp;a=X" target="_blank" rel="nofollow">X</a>, <a xmlns="http://www.w3.org/1999/xhtml" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4641435-1&amp;h=1282341048&amp;u=https%3A%2F%2Fwww.facebook.com%2Filluminainc&amp;a=Facebook" target="_blank" rel="nofollow">Facebook</a>, <a xmlns="http://www.w3.org/1999/xhtml" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4641435-1&amp;h=3267236543&amp;u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fillumina&amp;a=LinkedIn" target="_blank" rel="nofollow">LinkedIn</a>, <a xmlns="http://www.w3.org/1999/xhtml" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4641435-1&amp;h=2728386269&amp;u=https%3A%2F%2Fwww.instagram.com%2Filluminainc&amp;a=Instagram" target="_blank" rel="nofollow">Instagram</a>, <a xmlns="http://www.w3.org/1999/xhtml" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4641435-1&amp;h=3102379406&amp;u=https%3A%2F%2Fwww.tiktok.com%2F%40illuminainc&amp;a=TikTok" target="_blank" rel="nofollow">TikTok</a>, and <a xmlns="http://www.w3.org/1999/xhtml" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4641435-1&amp;h=661781424&amp;u=https%3A%2F%2Fwww.youtube.com%2Fuser%2FIlluminaInc&amp;a=YouTube" target="_blank" rel="nofollow">YouTube</a><u xmlns="http://www.w3.org/1999/xhtml">.</u> </p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">About Veritas Genetics Powered by Fuze Health</b></p><p xmlns="http://www.w3.org/1999/xhtml">Veritas Genetics is a leader in clinical genomics, offering advanced human-genome sequencing and interpretation services to enable accurate diagnosis, personalized prevention, and improved healthcare decision-making. Veritas is part of Fuze Health, a technology-powered home health screening, genomics and pharmacy services provider committed to transforming patient experiences and enabling healthcare partners – including care providers, health plans, employers and life sciences companies – to excel in an outcomes-focused system.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">Contacts</b>  </p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">Investors:</b> <br xmlns="http://www.w3.org/1999/xhtml"></br>Illumina Investor Relations <br xmlns="http://www.w3.org/1999/xhtml"></br>858-291-6421 <br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" href="mailto:IR@illumina.com" target="_blank" rel="nofollow">IR@illumina.com</a> </p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">Media:</b> <br xmlns="http://www.w3.org/1999/xhtml"></br>Christine Douglass <br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" href="mailto:PR@illumina.com" target="_blank" rel="nofollow">PR@illumina.com</a> </p>



<p xmlns="http://www.w3.org/1999/xhtml" id="PURL"><img xmlns="http://www.w3.org/1999/xhtml" title="Cision" width="12" height="12" alt="Cision" src="https://edge.prnewswire.com/c/img/favicon.png?sn=LA10450&amp;sd=2026-03-16"></img> View original content:<a xmlns="http://www.w3.org/1999/xhtml" id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/illumina-advances-preventive-genomics-through-strategic-consortium-with-veritas-genetics-302714332.html" target="_blank">https://www.prnewswire.com/news-releases/illumina-advances-preventive-genomics-through-strategic-consortium-with-veritas-genetics-302714332.html</a></p><p xmlns="http://www.w3.org/1999/xhtml">SOURCE Illumina, Inc.</p>

Illumina has announced a strategic collaboration with Veritas Genetics to integrate preventive genomics into everyday healthcare. This partnership aims to utilize whole-genome sequencing for proactive risk identification and personalized prevention, potentially positioning ILMN for expanded market opportunities and revenue growth.

Illumina advances preventive genomics through strategic consortium with Veritas Genetics

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News